Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

346
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
346
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

828
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
828

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

Neuro-oncology advances·2022
Same author

"You can observe a lot by just watching" (Yogi Berra).

Neuro-oncology·2021
Same author

Leptomeningeal metastases: how best to assess response.

Neuro-oncology·2020
Same author

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Neuro-oncology·2018
Same author

Leptomeningeal metastasis.

Handbook of clinical neurology·2018
Same author

Immunochemotherapy, the New Standard of Care for Primary CNS Lymphoma: However, Which One?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2017

Related Experiment Video

Updated: Apr 20, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

3.2K

Glioblastoma in the elderly.

Marc C Chamberlain1

  • 1Department of Neurology and Neurological Surgery, University of Washington/Fred Hutchison Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave East MS G4940, Box 19023, Seattle, WA, 98109, USA, chambemc@uw.edu.

Cancer Treatment and Research
|December 4, 2014
PubMed
Summary

Standard glioblastoma (GBM) treatment lacks consensus for elderly patients (age ≥70 years). Options include supportive care, radiation therapy (RT), temozolomide (TMZ) chemotherapy, or combined RT + TMZ.

Area of Science:

  • Neuro-oncology
  • Geriatric Medicine
  • Radiation Oncology

Background:

  • Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options for elderly patients.
  • There is no universally accepted standard of care for patients aged 70 years and older diagnosed with GBM.
  • Current treatment strategies vary widely, impacting patient outcomes and quality of life.

Purpose of the Study:

  • To review and summarize the current treatment landscape for elderly patients with newly diagnosed glioblastoma.
  • To highlight the range of therapeutic options, from best supportive care to combined modality treatments.
  • To inform clinical decision-making and future research directions in geriatric neuro-oncology.

Main Methods:

  • Literature review of existing clinical trials and treatment guidelines for elderly GBM patients.

More Related Videos

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.6K
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

3.2K
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.6K
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.8K
  • Analysis of treatment modalities including supportive care, radiation therapy (RT), temozolomide (TMZ), and combined RT + TMZ.
  • Comparison of treatment approaches based on patient age (≥70 years) and performance status.

    • Main Results:

    • Treatment options for elderly GBM patients include supportive care only, RT alone (often hypofractionated), TMZ chemotherapy alone, or combined RT + TMZ.
    • The standard of care for younger patients (RT + TMZ) is also considered for elderly patients, but its applicability and benefit require further investigation.
    • Hypofractionated RT schedules are frequently employed in this age group.

    Conclusions:

    • The optimal treatment strategy for elderly patients with glioblastoma remains an open question.
    • Individualized treatment plans considering patient factors are crucial.
    • Further research is needed to establish evidence-based standards of care for this vulnerable population.